GlassScriptPhysician profile
Mitzi N Gardner
NPI 1245481811
$1,452.45
in general payments reported to CMS, 2019-2025
19 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $93.78 · 2023: $426 · 2024: $250 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.57 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $372.63 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $222.76 | 2023-2025 | |
| Pfizer INC. | $119.08 | 2021-2025 | |
| Lilly USA, LLC | $100.24 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $99.46 | 2021-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $98.17 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.22 | 2025 | Caplyta |
| Exact Sciences Corporation | $75.37 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $65.99 | 2023 | |
| Xeris Pharmaceuticals, INC. | $37.88 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $32.63 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $32.48 | 2023 | Farxiga |
| Krystal Biotech INC | $18.45 | 2025 | Vyjuvek |
| Inspire Medical Systems, INC. | $15.26 | 2025 | Inspire |
| Corcept Therapeutics | $15.08 | 2024 | Korlym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $14.76 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $13.92 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $13.31 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.